San­doz un­veils glob­al ac­tion plan to im­prove ac­cess to biosim­i­lars

As the spot­light trains on ac­cess to biosim­i­lars, No­var­tis’ gener­ics unit on Thurs­day re­leased a glob­al ac­tion plan to boost biosim­i­lar adop­tion by 2030.

The ac­tion plan is part of the Act4Biosim­i­lars ini­tia­tive launched by San­doz last year and led by a steer­ing com­mit­tee of pa­tient ad­vo­cates, health­care pro­fes­sion­als and oth­er ex­perts. The plan in­cludes rec­om­men­da­tions for stream­lin­ing the reg­u­la­to­ry process, dri­ving pa­tient aware­ness and fight­ing mis­in­for­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER